Mobile

A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to adu...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-012188-32

A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to adults aged 66 years and older compared to Fluarix™ administered to adults aged 19-43 years and 66 years and older, who previously participated in the 111737 study

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the safety and reactogenicity during the entire study period in subjects aged 66 years or older (previously enrolled in the 111737 study) vaccinated with the FLU NG vaccine or with Fluarix, and in subjects aged 19-43 years (previously enrolled in the 111737 study) vaccinated with Fluarix

Critère d'inclusion

  • Immunization against influenza in male and female subjects aged 19-43 years and 66 years or older

Liens